Iovance Biotherapeutics, Inc. (IOVA)
13.62
-1.10
(-7.47%)
USD |
NASDAQ |
Oct 16, 16:00
13.57
-0.05
(-0.37%)
After-Hours: 20:00
Iovance Biotherapeutics Research and Development Expense (Annual) : 300.27M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 300.27M |
| December 31, 2024 | 282.34M |
| December 31, 2023 | 344.08M |
| December 31, 2022 | 294.78M |
| December 31, 2021 | 259.04M |
| December 31, 2020 | 201.73M |
| December 31, 2019 | 166.02M |
| December 31, 2018 | 99.83M |
| December 31, 2017 | 71.62M |
| Date | Value |
|---|---|
| December 31, 2016 | 28.04M |
| December 31, 2015 | 15.47M |
| December 31, 2014 | 2.705M |
| December 31, 2013 | 1.329M |
| December 31, 2012 | 1.656M |
| December 31, 2011 | 1.756M |
| December 31, 2010 | |
| December 31, 2009 | 0.00 |
| December 31, 2008 | 0.0302M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Halozyme Therapeutics, Inc. | 81.49M |
| AVITA Medical, Inc. | 20.84M |
| CareDx, Inc. | 71.43M |
| Amgen, Inc. | 6.974B |
| Xencor, Inc. | 239.43M |